Schonfeld Strategic Advisors LLC Has $1.59 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Schonfeld Strategic Advisors LLC decreased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 12.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 47,620 shares of the biotechnology company’s stock after selling 6,616 shares during the quarter. Schonfeld Strategic Advisors LLC’s holdings in Exelixis were worth $1,586,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Blue Trust Inc. lifted its position in shares of Exelixis by 134.7% in the 4th quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company’s stock worth $476,000 after acquiring an additional 8,208 shares during the period. Raymond James Financial Inc. acquired a new stake in Exelixis during the fourth quarter worth $17,046,000. Range Financial Group LLC bought a new stake in Exelixis in the 4th quarter valued at $994,000. Allspring Global Investments Holdings LLC raised its stake in shares of Exelixis by 82.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock valued at $52,884,000 after buying an additional 704,786 shares in the last quarter. Finally, Inspire Investing LLC raised its stake in shares of Exelixis by 25.0% in the 4th quarter. Inspire Investing LLC now owns 36,659 shares of the biotechnology company’s stock valued at $1,221,000 after buying an additional 7,331 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Guggenheim reaffirmed a “buy” rating and issued a $42.00 price target on shares of Exelixis in a research note on Wednesday, February 12th. Citigroup boosted their target price on shares of Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. Barclays increased their target price on shares of Exelixis from $25.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. StockNews.com upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, February 19th. Finally, Morgan Stanley raised shares of Exelixis from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $30.00 to $40.00 in a report on Monday, January 27th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.59.

Insider Buying and Selling at Exelixis

In related news, Director Mary C. Beckerle sold 12,210 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $34.88, for a total value of $425,884.80. Following the sale, the director now directly owns 30,406 shares of the company’s stock, valued at $1,060,561.28. This trade represents a 28.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.98, for a total value of $1,946,479.28. Following the completion of the sale, the executive vice president now owns 303,310 shares in the company, valued at approximately $11,216,403.80. This represents a 14.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 141,851 shares of company stock worth $5,236,046 over the last three months. Company insiders own 2.85% of the company’s stock.

Exelixis Stock Down 7.5 %

EXEL opened at $36.86 on Wednesday. The firm has a 50-day moving average price of $36.98 and a 200-day moving average price of $35.21. Exelixis, Inc. has a twelve month low of $20.14 and a twelve month high of $40.26. The company has a market capitalization of $10.16 billion, a price-to-earnings ratio of 20.82, a PEG ratio of 1.13 and a beta of 0.25.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, sell-side analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.